Safety and Tolerability Trial of Arimoclomol for Sporadic Inclusion Body Myositis
Latest Information Update: 01 Dec 2022
At a glance
- Drugs Arimoclomol (Primary)
- Indications Inclusion body myositis
- Focus Adverse reactions
- 11 Feb 2020 Results published in the CytRx Corporation Media Release.
- 05 May 2014 New trial record
- 03 May 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.